2009-11-11 14:00:02 -
Research and Markets ( www.researchandmarkets.com/research/476754/pipeline_insight : 
) has announced the addition of the " Pipeline Insight: Colorectal Cancer - Growing Trend Towards Personalized Medicine : " report to their offering.
CRC incidence will be over 490,000 cases by 2018 in the seven major markets. This large patient base will translate into a high commercial potential for the development of
novel, more effective therapies.
Currently, there are 77 agents in development for CRC, 4 of which are in late-phase development. Collectively, they are forecast to achieve sales of $1,398m by 2018.
Scope
- Examination of the CRC pipeline with in-depth clinical and commercial profiles of Phase III candidates
- Seven major pharmaceutical market sales forecasts for Phase III pipeline products through to 2018
- Segmentation and analysis of the current CRC pipeline by developmental phase, drug class and company
- Insight and analysis of market potential including commercial opportunity, epidemiology and discussion of unmet needs
Highlights of this title
- The CRC pipeline consists of 77 drugs, of which 60% are molecular targeted therapies (MTTs), 22% are immunotherapies, and 17% are cytotoxic therapies. MTTs constitute the bulk of the CRC pipeline.
This is in line with R&D in other tumor types, where there is a shift away from standard cytotoxic therapies towards MTTs and personalized medicine.
- The late-phase CRC pipeline consists only of MTTs. Except for one agent; all the others are being investigated in previously-treated patients. Drug developers appear to be pursuing approval for treatment in the second-line setting where barriers to market entry are lower and the high level of unmet need may facilitate a drug's uptake and approval.
- Aflibercept (VEGF-Trap; Regeneron/Sanofi-Aventis) is forecast to achieve the highest level of sales among the late-phase pipeline candidates in the CRC market, generating £604m by 2018 in the seven major pharmaceutical markets.
Key reasons to purchase this title
- Identify key drugs and companies within the CRC pipeline based on sales forecasts to 2018 and Datamonitor drug assessment.
- Characterize unmet need and poorly served patient subsets within the CRC market and assess the potential for pipeline products to fulfil them.
- Segmentation and analysis of the current CRC pipeline by developmental phase, drug class, company and indication.
Key Topics Covered:
Executive Summary
- Strategic scoping and focus
- Datamonitor insight into the colorectal cancer market
- Datamonitor pipeline assessment summary
- Related reports
- Upcoming related reports
Pipeline Overview and dynamics
- Key findings
- Pipeline overview
- Pipeline summary
- Novel molecular targeted therapies dominate the current late-phase colorectal cancer pipeline
- Comparative forecasts
- Datamonitor pipeline assessment summary
- Key companies involved in the colorectal cancer (CRC) pipeline
- Amgen
- AstraZeneca
- Roche
- Key R&D company strategies
- Ongoing shift towards molecular targeted therapies in colorectal cancer
- Line extensions of already marketed drugs
Colorectal cancer - Market Potential
- Colorectal cancer is one of the 'big four' tumors and numbers are set to rise over the next decade
- Histology
- Risk factors
- CRC is predominantly a disease of the elderly
- People with CRC in the family have a high risk of developing the disease
- Western style diets contribute to CRC incidence
- Rise of CRC in the migrant population
- Symptoms
- Screening and diagnosis
- Fecal occult blood test is the most commonly used screening method
- Endoscopic methods are not ideal for CRC screening
- CRC screening remains fragmented between countries
- Patient segmentation
- Proper staging is essential to the design of treatment plans
- Epidemiology
- Seven major markets
- CRC cases are expected to rise in line with the aging world population
- Low detection in the early stages of the disease results in a high mortality rate
- Rest of the world
- Current treatment options
- Surgery remains the primary treatment choice for early-stage CRC
- Adjuvant therapy extends disease-free survival in Stage III patients
- Combination chemotherapy is the standard of care in metastatic disease
- Avastin is used predominantly in the US in the first-line setting
- Erbitux is indicated for use in patients with wild-type KRAS status
- Vectibix has limited uptake in the treatment of the disease
- Current comparator therapy
- Eloxatin (oxaliplatin; Sanofi-aventis)
- Unmet need in colorectal cancer (CRC)
- Better screening approaches needed to decrease mortality rates
- There is a need for more effective therapies in both early-stage and advanced disease
- Biomarkers and the selection of patients may help improve outcomes
- Target product profile versus current level of attainment
R&D Approach
- Key findings
- Clinical trial design in colorectal cancer (CRC)
- Patient selection
- Clinical trial endpoints in oncology
- Overall survival
- Disease-free survival
- Overall response rates
- Progression-free survival
- Disease control
- Toxicity
Pipeline Analysis & Forecasts: Molecular Targeted Therapies
- Key findings
- Overview of the molecular targeted therapies
- Pipeline summary
Innovative Early-Stage Approaches
- Key findings
- Overview of early-stage innovative projects
- TRAIL
- Insulin-like growth factor receptor (IGFR)
- MAP kinase pathway
- The future of treatment of colorectal cancer (CRC)
- Molecular markers will become an important part of therapy for patient selection
- The future will see more combination therapies to target multiple pathways
- Increased understanding of cancer evolution should result in a large range of potential drug targets
- Bibliography
- Journals
- Websites
APPENDIX
Companies Mentioned.
- AstraZeneca PLC
- Biogen Idec, Inc.
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Genentech, Inc.
- Human Genome Sciences, Inc.
- IMS Health
- Keryx Biopharmaceuticals, Inc.
- Merck KGaA
- Schering-Plough Corporation
For more information visit
www.researchandmarkets.com/research/476754/pipeline_insight :
Source: Datamonitor
Research and MarketsLaura Wood, Senior Manager,
press@researchandmarkets.com : mailto:press@researchandmarkets.com U.S.
Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716
